Patent · US Active

Quinazoline derivatives for the treatment of cancer diseases

US9539258B2 · kind B2 · utility

1Cited by

34References

5Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Flavio Solca · Wien, AT
Andree AMELSBERG · Southbury, US
Jacobus Van Meel · Biberach, DE
Anke Baum · Alland, AT
Gerd Stehle · Heidelberg, DE

Key dates

Filing date	Jun 15, 2015
Grant date	Jan 10, 2017
Priority date	—
Expiry date	Jun 15, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the use of quinazolines of formula (I),wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.